Outcomes of Chemotherapy for Microsatellite Instable–High Metastatic Colorectal Cancers
Flavio Lejbkowicz
JCO precision oncology, 2018
View PDFchevron_right
Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability
Adrien Melis
JAMA Oncology
View PDFchevron_right
Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials
Imran chaudhary
Investigational new drugs, 2018
View PDFchevron_right
Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis
Jean-françois Morere
European Journal of Cancer, 2009
View PDFchevron_right
Pathologic Factors Associated with Prognosis after Adjuvant Chemotherapy in Stage II/III Microsatellite-Unstable Colorectal Cancers
Gyeong Kang
Journal of pathology and translational medicine, 2015
View PDFchevron_right
Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer
Antoine Hollebecque
European Journal of Cancer, 2020
View PDFchevron_right
Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
Eva Hofsli
British Journal of Cancer, 2022
View PDFchevron_right
Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142
Alain Hendlisz
Journal of Clinical Oncology
View PDFchevron_right
Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes
Golo Ahlenstiel
Cancers
View PDFchevron_right
Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015
Nick Pavlakis
Expert review of anticancer therapy, 2016
View PDFchevron_right
Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer
Adam Barsouk
Medical Sciences, 2019
View PDFchevron_right
Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis
O. Schischmanoff
Anticancer research, 2009
View PDFchevron_right
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group
Emiliano Tamburini
BMC cancer, 2017
View PDFchevron_right
Prediction of Response to Immune Checkpoint Blockade in Patients with Metastatic Colorectal Cancer with Microsatellite Instability
Magali Svrcek
Annals of Oncology, 2023
View PDFchevron_right
Microsatellite Instability and Survival in Stage II Colorectal Cancer: A Systematic Review and Meta-analysis
Antonio Varricchio
Anticancer Research
View PDFchevron_right
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
Yoshito Komatsu
Annals of Oncology, 2017
View PDFchevron_right
Outcomes of surgical resection in microsatellite instable colorectal cancer after immune checkpoint inhibitor treatment
Magali Svrcek
British Journal of Surgery, 2022
View PDFchevron_right
Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer
Jeffrey Clark
Cancer
View PDFchevron_right
Randomized clinical trials in advanced and metastatic colorectal carcinoma
Margo Shoup
Surgical oncology clinics of North America, 2002
View PDFchevron_right
Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study
Estelle Cauchin
Journal of the National Cancer Institute, 2016
View PDFchevron_right
RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Results of the GERCOR NIPICOL phase II study
Magali Svrcek
Journal of Clinical Oncology, 2020
View PDFchevron_right
Improving outcomes in colorectal cancer: Where do we go from here?
Michel Ducreux
European Journal of Cancer, 2013
View PDFchevron_right
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
Edith Mitchell
Journal of Clinical Oncology, 2009
View PDFchevron_right
Safety of Nivolumab plus Low‐Dose Ipilimumab in Previously Treated Microsatellite Instability‐High/Mismatch Repair‐Deficient Metastatic Colorectal Cancer
Leighanne Hartman
The Oncologist, 2019
View PDFchevron_right
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009
N. Pavlidis
Annals of Oncology, 2010
View PDFchevron_right
Exploring alternative individualized treatment strategies in colorectal cancer
Heinz-josef Lenz
Clinical colorectal cancer, 2007
View PDFchevron_right
Current and emerging therapies for metastatic colorectal cancer: Applying research findings to clinical practice
Iván Henríquez
American Journal of Health-System Pharmacy, 2008
View PDFchevron_right
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
Louise Nott
BMC Cancer, 2016
View PDFchevron_right
Microsatellite Instability, Prognosis and Drug Sensitivity of Stage II and III Colorectal Cancer: More Complexity to the Puzzle
Fred Bosman
JNCI Journal of the National Cancer Institute, 2011
View PDFchevron_right
Impact of Complete Response to Chemotherapy on Overall Survival in Advanced Colorectal Cancer: Results From Intergroup N9741
Barbara Pockaj
Journal of Clinical Oncology, 2007
View PDFchevron_right
Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data
Ansgar Lange
The oncologist, 2014
View PDFchevron_right